As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

A new twist on a decades-old anticancer strategy has shown powerful effects against multiple cancer types in a preclinical study from researchers in the Perelman School of Medicine at the University ...

Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...

Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Otulfi ® received MHRA approval for both subcutaneous and intravenous formulations, to ...

Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing MENLO PARK, ...

wherein its nuclear translocation increases NF-κB activity promoting resistance to platinum-based chemotherapy in colorectal cancer.

Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a ...

Alphaf-001 is under clinical development by Alpha Fusion and currently in Phase I for Follicular Thyroid Cancer.

It was Carter's first lesson since detailing the intravenous drug doses and radiation treatment planned to treat melanoma ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

When you think of which slot machines pay the best, your mind probably immediately goes to high RTP slots, which is partially correct. However, volatility, bonus rounds, free spins rounds, gameplay, ...

Yet, initial treatment of AHF today is similar to 40 years ago. Multiple studies have yielded new insights regarding initial management, with regards to both treatment and strategies of care.